Dose-Response in Radionuclide Therapy of Thyroid Cancer
- Determine the relationship between estimated absorbed dose of iodine I 131 and tumor
response or normal organ toxicity for different dosimetric measures, using data derived
from clinical radionuclide therapy studies in patients with thyroid cancer.
OUTLINE: Patients receive oral dosimetric iodine I 131 (^131I) on day 2 and then undergo
nuclear medicine imaging at 0.5-4 hours, 24, 48, and 72 hours after dosimetric ^131I.
Single-photon emission computed tomography (SPECT)/CT scans are performed at 0.5-4 hours and
24 or 48 hours over the head and neck region, including the salivary glands. Subsequent
SPECT/CT scans are performed over the candidate tumor sites. Patients undergo ^131I therapy
on day 11.
Saliva is collected on days 1 and 2, weeks 2 and 4, and months 3 and 6 to measure saliva
flow rate. Blood is collected at baseline and periodically during study to measure FLT3
PROJECTED ACCRUAL: A total of 96 patients will be accrued for this study.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Relationship between estimated absorbed dose and normal organ toxicity
July '06 to Sept '10
George Sgouros, PhD
Sidney Kimmel Comprehensive Cancer Center
United States: Institutional Review Board
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||Baltimore, Maryland 21231-2410|